L Vuorilehto
Overview
Explore the profile of L Vuorilehto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kortesuo P, Ahola M, Kangas M, Leino T, Laakso S, Vuorilehto L, et al.
J Control Release
. 2001 Oct;
76(3):227-38.
PMID: 11578738
The effect of alkyl substitution of the silica xerogel matrix on the release rate of dexmedetomidine was evaluated. Silica sol was processed by either casting or spray drying. When the...
2.
Huupponen R, Karhuvaara S, Anttila M, Vuorilehto L, Scheinin H
Clin Pharmacol Ther
. 1995 Nov;
58(5):506-11.
PMID: 7586944
Objective: To evaluate the pharmacokinetics, systemic effects and clinical applicability of buccally administered atipamezole in healthy volunteers. Methods: The study was carried out in two parts. In the first part,...
3.
Salonen S, Vuorilehto L, Vainio O, Anttila M
J Vet Pharmacol Ther
. 1995 Oct;
18(5):328-32.
PMID: 8587149
Medetomidine, an alpha 2-adrenoceptor agonist, is a potent sedative and analgesic agent in the dog. When necessary, its action can be effectively antagonized by atipamezole. The present work was designed...
4.
Macdonald E, Vartiainen J, Jasberg K, Vuorilehto L, Salonen J, Urtti A
Curr Eye Res
. 1993 May;
12(5):451-60.
PMID: 8102091
Dexmedetomidine is a selective alpha 2-adrenoceptor agonist which has previously been shown to reduce the ocular pressure of normotensive rabbits as well as those with pressures artificially elevated by laser...
5.
Dyck J, Maze M, Haack C, AZARNOFF D, Vuorilehto L, Shafer S
Anesthesiology
. 1993 May;
78(5):821-8.
PMID: 8098191
Background: This investigation extended the pharmacokinetic analysis of our previous study, of intravenous dexmedetomidine in 10 healthy male volunteers, and prospectively tested the resulting compartmental pharmacokinetics in an additional six...
6.
Dyck J, Maze M, Haack C, Vuorilehto L, Shafer S
Anesthesiology
. 1993 May;
78(5):813-20.
PMID: 8098190
Background: Dexmedetomidine is an alpha 2 agonist with potential utility in clinical anesthesia for both its sedative and sympatholytic properties. Methods: The pharmacokinetics and hemodynamic changes that occurred in ten...
7.
Scheinin H, Karhuvaara S, Olkkola K, Kallio A, Anttila M, Vuorilehto L, et al.
Clin Pharmacol Ther
. 1992 Nov;
52(5):537-46.
PMID: 1358496
The pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine--a novel alpha 2-adrenergic receptor agonist under development for preanesthetic use--were studied in healthy male volunteers. Single intramuscular doses of dexmedetomidine (0.5, 1.0, and...
8.
Salonen J, Vuorilehto L, Gilbert M, Maylin G
Eur J Drug Metab Pharmacokinet
. 1992 Jan;
17(1):13-20.
PMID: 1499593
Horse urine was investigated for metabolites by chromatography and mass spectrometry following the oral administration of the large animal analgesic sedative detomidine to two stallions and intravenous administration of [3H]-detomidine...
9.
Vuorilehto L, Salonen J, Anttila M
J Chromatogr
. 1990 Aug;
530(1):137-40.
PMID: 2277103
No abstract available.
10.
Sipila H, Kangas L, Vuorilehto L, Kalapudas A, Eloranta M, Sodervall M, et al.
J Steroid Biochem
. 1990 Jun;
36(3):211-5.
PMID: 2142235
Toremifene was labelled to a specific activity of about 20 microCi/mmol with tritium at positions 3 and 5 in the para-substituted phenyl ring. At these positions tritium is not eliminated...